Biotechnology Company
Appears in 1 story
Phase 3 RASolute 302 succeeded April 2026 (60% death risk reduction); FDA expanded access authorized April 30, 2026; NDA filing planned under Commissioner's National Priority Voucher; ASCO plenary presentation scheduled May 31, 2026; $2.225B raised in April 2026 capital offerings
In April 2026, daraxonrasib became the first drug to beat chemotherapy in a Phase 3 pancreatic cancer trial, cutting death risk by 60% and extending median survival from 6.7 to 13.2 months. The FDA authorized expanded access May 1; Revolution Medicines plans to file a New Drug Application and present full Phase 3 data at the ASCO Annual Meeting on May 31, 2026.
Updated 5 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
